Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices

Abstract

Re-treatment with bortezomib was common; novel agents were reserved for later therapy lines. Overall, the observed PFS associated with real-world treatment sequences were shorter than those reported in clinical trials.